Payman Khales Assumes Role as Integer President and CEO

Integer Holdings Corporation (NYSE: ITGR), a prominent global player in the medical device contract development and manufacturing sector, has officially announced the appointment of Payman Khales as President and Chief Executive Officer, following a planned leadership transition that began in April 2025. Khales succeeds Joseph Dziedzic, who is set to retire after eight years of impactful leadership, and will remain as an advisor until March 31, 2026, to help facilitate a seamless transition.

A seasoned executive, Khales joined Integer in 2018 as the head of the Cardio & Vascular business, where he implemented a highly effective market-centric strategy, resulting in a remarkable doubling of sales over seven years and significant profitability improvements. His most recent position as Chief Operating Officer saw him oversee Integer's two business units and global operations, further solidifying the company’s reputation as a key strategic partner to medical device firms and original equipment manufacturers (OEMs) worldwide.

In a statement about his new role, Khales expressed enthusiasm for the opportunities that lie ahead, emphasizing the company's commitment to innovation and collaboration aimed at delivering life-enhancing medical technologies globally. He thanked Dziedzic for his mentorship and pledged to lead Integer with a focus on creating value through team synergy and customer engagement.

Before his tenure at Integer, Khales held influential leadership roles at CECO Environmental Corp. and Ingersoll Rand Company. He holds an Executive MBA from Indiana University’s Kelley School of Business and a Bachelor’s degree in Mechanical Engineering from École Polytechnique de Montréal.

As a leading contract development and manufacturing organization for medical devices, Integer remains dedicated to enhancing patient outcomes through innovative solutions, with well-known brands such as Greatbatch Medical and Lake Region Medical under its umbrella.

The recent leadership transition at Integer Holdings Corporation (NYSE: ITGR), with Payman Khales assuming the role of President and CEO, signifies a critical moment for the company and potentially presents a compelling investment opportunity. Khales’s proven track record in driving significant sales growth and operational excellence during his tenure as President of the Cardio & Vascular business and subsequently as COO is a strong indicator of his capability to lead the firm toward future successes.

Since its inception, Integer has been a key player in the medical device contract development and manufacturing landscape, catering to high-demand sectors such as cardiac rhythm management and neuromodulation. With Khales’s emphasis on innovation and customer collaboration, investors should anticipate a strategic refocusing that could enhance product offerings and market penetration, thereby potentially driving revenue growth.

While Joseph Dziedzic leaves behind a legacy built on stability and growth, the transitional period offers opportunities for Khales to implement fresh initiatives that could rejuvenate the company’s market presence. The healthcare sector is poised for increased investment, especially in medical technologies amid ongoing advancements and rising demand for innovative solutions. Khales’s plans to foster collaboration with customers and deliver life-changing products align well with current market trends, indicating a possible strengthening of Integer’s position as a preferred partner in medical device manufacturing.

For investors, closely monitoring Integer’s performance in the short term will be crucial, especially as Khales and his team work to articulate specific strategies and goals. Strengthening market share and enhancing customer relationships in line with Khales’s vision could lead to improved stock performance. Given these dynamics, there is a strong rationale for considering Integer as a promising addition in a diversified medical device portfolio.